Combination chemotherapy of vinorelbine and cisplatin: A phase I pharmacokinetic study in patients with metastatic solid tumors

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 553-560

  Delord, Jean Pierre ^a   Puozzo, Christian ^a,c   Lefresne, Florence ^b   Bugat, Roland ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b Centre d'Immunologie Pierre Fabre   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Cisplatin; Drug drug interaction; Pharmacokinetics; Phase I; Vinorelbine orale

Indexed keywords

CISPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; AUDITORY DISCRIMINATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; PERCEPTION DEAFNESS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; SIDE EFFECT; SINUS TACHYCARDIA; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; VINBLASTINE;

EID: 61449092990     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics. CA Cancer J Clin 56(2): 106-130, 2006.
2. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT and Sommerfield MR: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22(24): 5018-5020, 2004.
3. Clinical Practice Guidelines for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15(8): 2996-3018, 1997.
4. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Constanzo F, Frontini L and Tonato M; Italian Lung Cancer Project: Phase III randomised trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20(21): 4285-4291, 2002.
5. Gralla RJ, Gatzemeier U, Gebbia V, Huber R, O'Brien M and Puozzo C: Oral vinorelbine in the treatment of non-small cell lung cancer. Drug 67(10): 1403-1410, 2007.
6. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Rivière A, Lianes P, Chomy P and Cigolari S: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12(2): 360-367, 1994.
7. Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Solal-Celigny P, Badri N and Besenval M: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 5(1): 37-42, 1994.
8. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR and Livingston RB: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16: 2459-2465, 1998.
9. Han JY, Kim KW, Kim JA, Kang JH, Jin JY, Hong YS, Park SY, Song JS, Park JW, Kim HK, Lee KS and Choi BG: A phase II study of a daily x4 schedule of vinorelbine plus cisplatin for advanced non-small cell lung cancer. Jpn J Clin Oncol 30(10): 435-439, 2000.
10. Le Chevalier T, Brisgand D, Soria JC, Douillard JY, Pujol JL, Ruffie P, Aberola V and Cigolari S: Long-term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6(1): 8-11, 2001.
11. Souquet PJ, Tan EH, Rodrigues Pereira J, Van Klaveren R, Price A, Gatzemeier U, Jaworski M, Burillon JP and Aubert D: GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small cell lung cancer patients. Ann Oncoi 13: 1853-1861, 2002.
12. Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N, Gebbia N, Valdesi M, Caruso M, Valenza R, Pezzella G, Colucci G and Grupo Oncologico Italia Meridionale: Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in state IIIB-IV non-small cell lung carcinoma: a prospective randomised study. Lung Cancer 37(2): 179-187, 2002.
13. Buccheri G, Ferrigno D and Giordano C: Cisplatin and vinorelbine remains a valid option for the front-line chemotherapy treatment of NSCLC. Anticancer Res 24: 4227-4236, 2004.
14. Cobo-Dols M, Gil-Calle S, Villar-Chamorro E, Alès-Diaz I, Carabantes-Ocon F, Alcalde-Garcia J, Gutierrez-Calderon V, Montesa-Pino A, Breton-Garcia JJ and Benavides-Orgaz M: Cisplatin plus continuous infusion vinorelbine for the treatment of advanced non-small cell lung cancer: a phase I-II study. Clin Transi Oncol 8(7): 519-524, 2006.
15. Chen YM, Yu CJ, Yang CH, Perng RP, Tsai CM, Shih JF, Cheng AL, Lefresne F, Barbier M, Pouget JC and Yang PC: A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 56: 89-95, 2007.
16. Hanigan MH and Devarajan P: Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1: 47-61, 2003.
17. Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J and Schlatter E: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 67(6): 1477-1484, 2005.
18. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I and Puozzo C: Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12(11): 1643-1649, 2001.
19. Focan C, Kreutz F, Leroy I, Blanchot G, Van Heugen JC, Aerts J and Puozzo C: Pharmacokinetics and mass-balance elimination of 3H-vinorelbine following IV and oral administration to patients. Proc Am Assoc Cancer Res (AACR) 2001, New Orleans, USA, Abst 2064.
20. Puozzo C, Zorza G, Guimbaud R, Van Heugen JC, De Graeve J, Chatelut E, Variol P, Canal P, Fahy J and Bugat R: Metabolism of vinorelbine in human: clinical application. Proc Am Assoc Cancer Res (AACR) 2000, San Francisco, USA, Abst 1781.
21. Bourgeois H, Vermerken J, Dark G, Jones A, Fumoleau P, Stupp R, Tourani J, Brain E, Lefresne F and Nguyen L: Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol 60(3): 407-13, 2007.
22. Bugat R, Variol P, Roché H, Fumoleau P, Robinet G and Senac I: The effects of food on the pharmacokinetic profile or oral vinorelbine. Cancer Chemother Pharmacol 50: 285-290, 2002.
23. Variol P, Nguyen L, Tranchand T and Puozzo C: A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 58: 472-476, 2002.
24. Nguyen L, Tranchand B, Puozzo C and Variol P: Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 53: 459-468, 2002.
25. Urien S, Bree F, Breillout F, Bastian G, Krikorian A and Tillement JP: Vinorelbine high-affinity binding to human platelets and lymhocytes: distribution in human blood. Cancer Chemother Pharmacol 32(3): 231-234, 1993.
26. Soudon J, Zorza G, Van Heugen JC, de Graeve J, Vincenti M, Imbert T and Puozzo C: Search for vinorelbine metabolite activity: an in vitro cytotoxicity study using human ovary and lung cancer cell lines. Proc Am Assoc Cancer Res (AACR) 2001, New Orleans, USA, Abst 2909.
27. Beulz-Riché D, Grudé P, Puozzo C, Sautel C, Filaquier C, Riche C and Ratanasavanh D: Characterisation of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 19: 545-553, 2005.
28. Van Heugen JC, De Graeve J, Zorza G and Puozzo C: New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. J Chromatogr A 926: 11-20, 2001.
29. Chatelut E, de Forni M, Canal P, Chevreau C, Roche H, Plusquellec Y, Johnson NP, Houin G and Bugat R: Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies. Ann Oncol 2(3): 217-221, 1991.
30. Kloft C, Appelius H, Siegert W, Schunack W and Jaehde U: Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther Drug Monit 21(6): 631-637, 1999.
31. Puozzo C, Ung HL and Zorza G: A high performance liquid chromatography method for vinorelbine and 4-O deacetyl-vinorelbine: a decade of routine analysis in human blood. J Pharm Biomed Anal 44: 144-149, 2007.
32. Martoni AA, Melotti B, Sperandi F, Giaquinta S, Piana E, Pavesi L, Da Prada G and Lelli G: Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study. Lung Cancer 60(3): 387-392, 2008.
33. Lévêque D, Jehl F, Quoix E and Breillout F: Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharm 32(12): 1096-1098, 1992.
34. Yamamoto N, Tamura T, Maeda M, Ando M, Shinkai T, Eguchi K, Ohe Y, Oshita F, Shiraishi J and Katsumata N: The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 36(2): 102-106, 1995.
35. Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, Schmitz PI, Stoter G and Verweij J: Relationship between the exposure to cisplatin DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73(12): 1569-1575, 1996.
36. Korst AE, van der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB and van der Vijgh WJ: Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 4(2): 331-336, 1998.
37. Goel R, Andrews PA, Pfeifle CE, Abramson IS, Kirmani S and Howell SB: Comparison of the pharmacokinetic of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy. Eur J Cancer 26(1): 21-27, 1990.
38. Boisdron-Celle M, Lebouil A, Allain P and Gamelin E: Pharmacokinetic properties of platinium derivatives. Bull Cancer 88(Suppl No): S14-19, 2001.